论文部分内容阅读
目的:观察甲氨蝶呤联合聚桂醇介入治疗对子宫瘢痕妊娠患者子宫壁厚度及月经恢复时间的影响。方法:选择2019年2月至2020年2月金华市文荣医院、金华市中心医院及义乌市妇幼保健院收治的子宫瘢痕妊娠患者60例为研究对象，按随机数字表法将其分为对照组（30例，子宫动脉栓塞治疗组）和研究组（30例，甲氨蝶呤联合聚桂醇介入治疗组）。观察比较两组治疗成功率、瘢痕处子宫壁厚度、月经恢复时间、住院时间、住院费用、不良反应发生率、治疗7ｄ后血清人绒毛膜促性腺激素（β-HCG）、超敏C反应蛋白（hs-CPR）水平及治疗前后子宫壁厚度变化情况。结果:治疗后，对照组成功率为70.00%（21/30），研究组成功率为96.67%（29/30），研究组明显高于对照组（χn 2=7.680，n P0.05）；治疗后，两组β-HCG水平均较治疗前降低（n t=22.803、10.233，均n P<0.001），hs-CPR水平均较治疗前升高（n t=-16.357、7.854，均n P<0.001），两组治疗后β-HCG及hs-CPR水平差异均有统计学意义（n t=20.413、-20.306，均n P<0.001）；研究组不良反应发生率为6.67%（2/30），对照组不良反应发生率为30.00%（9/30），两组差异有统计学意义（χn 2=5.455，n P<0.05）。治疗后，研究组患者月经恢复时间、住院时间及住院费用均优于对照组（n t=5.080、5.398、7.599，均n P0.05）。n 结论:甲氨蝶呤联合聚桂醇介入治疗子宫瘢痕妊娠，可有效提高其治疗成功率，快速恢复月经，缩短住院时间，安全性高。“,”Objective:To investigate the effects of ultrasound-guided intervention with methotrexate combined with lauromacrogol on uterine wall thickness and menstrual recovery time in patients with uterine scar pregnancy.Methods:Sixty patients with uterine scar pregnancy who received treatment in Jinhua Wenrong Hospital, Jinhua Central Hospital, and Yiwu Maternity and Children Hospital from February 2019 to February 2020 were included in this study. They were randomly assigned to receive either uterine artery embolization treatment (n n = 30, control group) or ultrasound-guided interventions with methotrexate combined with lauromacrogol (n n = 30, study group). The success rate of treatment, uterine wall thickness at the scar, menstrual recovery time, hospitalization time, hospitalization expenses, incidence of adverse reactions, serum levels of beta-human chorionic gonadotropin (β-HCG) and high sensitivity C-reactive protein (hs-CRP) after 7 days of treatment and uterine wall thickness before and after treatment were compared between the study and control groups.n Results:After treatment, the success rate of treatment in the study group was significantly higher than that in the control group [96.67% (29/30) n vs. 70.00% (21/30), χn 2 = 7.680, n P 0.05). After treatment, serum level of β-HCG in the control and study groups was significantly decreased ( n t = 22.803, 10.233, both n P < 0.01), and serum level of hs-CRP in the control and study groups was significantly increased ( n t = -16.357, 7.854, both n P < 0.001) compared with before treatment. After treatment, there were no significant differences in serum β-HCG and hs-CRP levels between the control and study groups ( n t = 20.413, -20.306, both n P < 0.05). After treatment, the incidence of adverse reactions in the study group was significantly lower than that in the control group [6.67% (2/30) n vs. 30.00% (9/30), χn 2 = 5.455,n P < 0.05). After treatment, menstrual recovery time, hospitalization time and hospitalization expenses in the study group were shorter or less than those in the control group ( n t = 5.080, 5.398, 7.599, all n P 0.05).n Conclusion:Ultrasound-guided intervention with methotrexate combined with lauromacrogol for treatment of uterine scar pregnancy can effectively increase the success rate of treatment, promote the restoration of menstruation, shorten the length of hospital stay, and is highly safe.